131885-80-8

Upstream product

• 7149-80-6 5-chloro-4-methyl-2-nitroaniline 
• 7149-79-3 N-(3-chloro-4-methylphenyl)acetamide 
• 7149-78-2 5-chloro-4-methyl-2-nitroacetanilide 
• 1026300-98-0 N-(4-Imidazol-1-yl-5-methyl-2-nitro-phenyl)-acetamide 
• 154164-40-6 N-(4-Imidazol-1-yl-3-methyl-phenyl)-acetamide 
• 154164-39-3 1-(2-Methyl-4-nitro-phenyl)-1H-imidazole 
• 461664-00-6 4-(1H-imidazol-1-yl)-3-methylaniline 
• 455-88-9 5-nitro-2-fluorotoluene 
• 143151-14-8 4-(1H-imidazol-1-yl)-5-methyl-2-nitroaniline 
• 131885-44-4 5-Imidazol-1-yl-4-methyl-2-nitro-phenylamine 

Relevant academic research and scientific papers

6-(1H-imidazol-1-yl)-7-nitro-2,3 (1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: Structure-activity relationships for the AMPA- type non-NMDA receptor

A novel series of quinoxalinediones possessing imidazolyl and related heteroaromatic substituents was synthesized and evaluated for their activity to inhibit [3H]AMPA binding from rat whole brain. From the structure- activity relationships, it was found that the 1H-imidazol-1-yl moiety could function as a bioisostere for the cyano and nitro groups, and that 6-(1H- imidazol-yl)-7-nitro-2,3(1H,4H)-quinoxalinedione (11) showed the most potent activity for the AMPA receptor. Compound 11 was evaluated for selectivity versus other excitatory amino acid receptors, and its action against AMPA at its receptor in the rat striatum was characterized. These data showed that compound 11 was a selective antagonist for the AMPA receptor with a K(i) value of 0.084 μM, being approximately equipotent with 2,3-dihydro-6-nitro- 7-sulfamoylbenzo(f)quinoxaline (3) (NBQX; K(i) = 0.060 μM). Compound 11 was also found to give protection against sound-induced seizure on DBA/2 mice at the minimum effective dose of 3 mg/kg ip (3; 10 mg/kg ip).

Cardiotonic Agents. Synthesis and Cardiovascular Properties of Novel 2-Arylbenzimidazoles and Azabenzimidazoles

Novel 2-arylbenzimidazoles and azabenzimidazoles were synthesized, and their inotropic action was evaluated.Changes in left ventricular pressure, dP/dt max, were measured as an index of cardiac contractility.The structural features that impart optimal inotropic activity are presented.The most potent compounds were evaluated orally in conscious dogs with implanted Konigsberg pressure transducers.To investigate the mechanism of action, the most potent compounds were tested for their calcium-sensitizing properties and their potential for the inhibition of phosphodiesterase.Two compounds, 1 and 41, showed interesting in vitro and oral activity without side effects.They have a more potent calcium-sensitizing effect than MCI-154 and are under further investigation.